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Tubular aggregates caused by serine active
site containing 1 (SERAC1) mutations in a
patient with a mitochondrial encephalopathy
Tubular aggregates (TAs) are cytoplasmic aggregates of
membranous tubules derived from the sarcoplasmic
reticulum and usually 50–70 nm in diameter [1]. They
may be seen in a range of genetic myopathies, including
gyrate atrophy caused by ornithine aminotransferase
deficiency, periodic paralysis and two disorders of
glycosylation caused by mutations in the GFPT1 and
DPAGT1 genes [2,3]. In addition, they may occur as a
minor or inconsistent feature in a wide range of
myopathies or be the predominant feature in idiopathic or
congenital myopathies [4]. However, the mechanisms
underlying TA formation remain poorly understood. We
now report the development of TAs in a patient with a lipid
remodelling disorder, providing new insight into the for-
mation of TAs.
We report the case of a 13-year-old boy with a progres-
sive mitochondrial encephalopathy in the Leigh syndrome
spectrum. He is the first child of healthy unrelated Bengali
parents and has an unaffected younger sister. He initially
presented on day one of life with transient neonatal lactic
acidosis and hyperammonaemia, which resolved with con-
servative management. Muscle biopsy in the neonatal
period revealed undetectable activity of succinate-
cytochrome c reductase [respiratory chain (RC) complexes
II + III], with normal activities of complexes I and IV
(Table 1). By 6 months, poor feeding and growth were
apparent, and at 18 months, he was treated with hearing
aids for bilateral sensorineural hearing loss (SNHL). At 2
years, he developed challenging behaviour, associated with
developmental regression. From 3 years, he had recurrent
chest infections, progressing to bronchiectasis. At 6.5
years, he had an episode of encephalopathy with status
dystonicus requiring invasive ventilation. At 9 years,
Nissen fundoplication was performed to treat severe gastro-
oesophageal reflux, and a Percutaneous Endoscopic
Gastro-Jejunostomy (PEG-J) was inserted. Muscle biopsy
was repeated at 12 years at the time of a gastrostomy
revision and revealed that RC activities were now
essentially normal, other than borderline reduction of
cytochrome c oxidase (COX, complex IV) activity (Table 1).
RC activities were normal in cultured skin fibroblasts
(Table 1). Now 13 years, he has microcephaly, optic
atrophy, severe dystonia and self-harm involving biting
and scratching. He receives prophylactic antibiotics to
prevent further respiratory infections and requires regular
suction and intermittent face mask oxygen. The results of
metabolic investigations are summarised in Table 1.
Neuro-imaging demonstrated abnormal signal in the
striatum bilaterally and associated atrophy in the caudate
heads.
A biopsy taken at 15 days of age from the left quadriceps
did not show significant diagnostic abnormalities
on routine histochemical stains including oxidative
stains [Nicotinamide adenine dinucleotide tetrazolium
reductase (NADH-TR), COX and succinate dehydrogenase
(SDH)] or fibre typing stains (Figure 1a–d). Furthermore,
ultrastructural examination only revealed prominent
nonmembrane-bound sarcoplasmic glycogen but no
abnormalities of mitochondrial ultrastructure (Figure 1e).
In contrast, a right quadriceps biopsy taken at 12 years
showed a number of abnormalities including some small,
predominantly angular, fibres (down to approximately
5 μm) (Figure 1f). There were occasional internal nuclei,
but these were not a prominent feature. There was no fibre
necrosis, regeneration or splitting. There was a fine vacu-
olation associated with Gömöri-positive material but no
ragged red fibres (Figure 1g). In a few areas, larger depos-
its of Gömöri-positive material were noted. There was
prominent lipid staining on Oil red O (Figure 1h). There
was some coarse staining on the NADH-TR stain, but
staining for SDH and COX was normal (Figure 1i). Fibre
typing with immunohistochemistry for fast and slow
myosin showed fast fibre predominance. There were small
fibres of both types. A few fibres stained for neonatal
myosin. We considered the possibility that the abnormal-
ity of fibre typing may have represented either a neuro-
genic component or a selective loss of slow fibres.
However, apart from angular atrophic fibres, specific fea-
tures to distinguish these possibilities were not seen.
Histochemical staining for adenylate deaminase showed
scattered dense aggregates of staining (Figure 1j). Stain-
ing for SERCA1 and SERCA2 showed a fibre-type pattern
but did not reveal significant aggregates. Electron micros-
copy showed frequent subsarcolemmal TAs composed of
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parallel collections of concentric double-walled tubules
(Figure 1k,l). The aggregates were very frequent but each
individually was relatively small, which may explain the
difficulty of recognizing them on histochemical stains.
The excess lipid noted histochemically was confirmed on
electron microscopy, but there were no abnormalities of
mitochondrial structure.
Genetic studies were performed with ethical approval
from the National Research Ethics Committee London
Bloomsbury, UK. In view of the low complex II + III activi-
ties in the first biopsy, the MT-CYB and BCS1L genes were
sequenced; no pathogenic mutations were identified. Full
mitochondrial genome sequencing was performed in
muscle from the second biopsy and was also normal. A
whole exome sequencing approach was then utilised to
further investigate presumed autosomal recessive Leigh
syndrome, using the Illumina HiSeq platform. Raw fastq
files were aligned to the hg19 reference genome using
Novoalign version 2.08.03 (Novocraft Technologies Sdn
Bhd, Malaysia). For this case sample, as well as a collection
of 2600 in-house control samples processed together, we
created gVCF files using the Haplotype Caller module of the
Genome Analysis Tool Kit (gatk) version 3.1.1 (Broad
Institute, USA). These individual gVCF files were combined
into combined gVCF of 100 samples, which were then
used for variant calling (using the GenotypeGVCF module
of gatk 3.1.1). Variants quality scores were recalibrated
according to GATK best practices separately for indels and
single nucleotide polymorphisms. Rare variants (defined
as an allele frequency <0.5% in-house control samples)
which were nonsynonymous, presumed loss of function or
splicing were prioritized. Of 21 388 exonic calls, eight
were rare homozygous, and 23 genes contained com-
pound heterozygous calls. In the mitochondrial gene
SERAC1 (serine active site containing 1), encoding a puta-
tive phosphatidylglycerol remodelling protein, we identi-
fied a known homozygous pathogenic splice mutation
c.1403 + 1G>C in exon 14. This mutation leads to a skip-
ping of exon 13 and nonsense mediated mRNA decay [5].
Both parents were heterozygous for this mutation, con-
firming segregation with disease in this family.
SERAC1 encodes a phospholipase which has been pos-
tulated to be involved in cholesterol trafficking and lipid
remodelling at the Mitochondria-associated endoplasmic
reticulum membranes (ER-MAM) interface [5]. The pres-
ence of TAs in our patient’s muscle at 12 years but not in
his neonatal biopsy suggests that sarcotubular structure
has altered in the intervening period, which we hypoth-
esise directly results from inefficient lipid remodelling as a
consequence of the SERAC1 mutations, leading to aggre-
gation of ER constituents. This hypothesis is supported by
the presence of TA-like structures in Chinese hamster
ovary cells overexpressing 3-hydroxy-3-methylglutaryl-
coenzymeA reductase, an ER enzyme involved in choles-
terol biosynthesis [6]. Delayed formation of TAs in our
patient fits with previous observations that TA formation
is slow in vivo, typically months in mice [7], which may
equate to years in humans. Previous reports of EM in
patients with SERAC1 mutations noted abnormal
mitochondrial architecture in liver [8] and muscle [5] but
not TAs. However, all previously reported muscle biopsies
appear to have been performed in infancy or very early
childhood [5,8–10], which likely explains the absence of
TAs in previous cases. Therefore, this is the first report of
the natural course of muscle pathology in SERAC1 defi-
ciency. SERAC1 deficiency is one of a growing family of
phospholipid biosynthesis and remodelling disorders,
Table 1. Metabolic investigations in a patient with SERAC1
deficiency
Investigation Results
Blood lactate Ranged from 5.7–7.4 mmol/L (reference
range 0.7–2.1)
CSF lactate 2.0 mmol/L (normal <2)
Urine organic
acids
Grossly raised lactate, pyruvate and
2-hydroxybutyrate with moderately raised
2-hydroxyisovalerate and mildly raised
2-oxo-isocaproate.
Strongly raised 3-methylglutaconate with
moderately raised 3-methylglutarate
Plasma amino
acids
Increased levels of
Alanine 587 μmol/L (150–450)
Glutamine 1143 μmol/L (480–800)
Tyrosine 394 μmol/L (30–120)
Proline 569 μmol/L (85–290)
Fibroblast enzyme
activities
Pyruvate dehydrogenase activity
0.85 nmoles/mg
Protein/min (reference range of 0.7–1.1)
Complex II + III 0.146 (0.07–0.243)
Complex IV 0.016 (0.007–0.036)
Muscle respiratory
chain enzyme
activities
At age 15 days
Complex I 0.101 (0.104–0.268)
Complex II and III undetectable
(0.040–0.204)
Complex IV 0.015 (0.014–0.034)
At age 12 years
Complex I 0.149 (0.104–0.268)
Complex II + III 0.103 (0.040–0.204)
Complex IV 0.013 (0.014–0.034)
CSF, Cerebrospinal fluid.
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which may affect the heart, skeletal muscle, brain or
peripheral nerves [11].
The variable RC deficiencies observed in SERAC1 defi-
ciency, with normal enzyme activities in some individuals
including the second biopsy in the patient reported
here, mean that abnormal RC activities cannot be used
as a screening test for this disorder. Rather, the presence
of a Leigh-like encephalopathy with SNHL and
3-methylglutaconic aciduria should trigger clinical suspi-
cion of 3-methylglutaconic aciduria with deafness,
encephalopathy and Leigh-like syndrome (MEGDEL syn-
drome), and sequence analysis of SERAC1 should be per-
formed. Moreover, our findings suggest that energy
deficiency is not the primary pathogenic mechanism in
SERAC1 deficiency and that abnormal subcellular aggre-
gate formation as a result of disordered lipid membrane
remodelling may be more important in the multisystemic
pathogenesis of this disorder, including deafness and pro-
gressive encephalopathy. Furthermore, based on the evi-
dence presented here, we suggest abnormal lipoprotein
aggregation may be a common pathogenic mechanism in
disorders of phospholipid biosynthesis and remodelling.
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